3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Smoldering Multiple Myeloma
1
Sarcoma
1
Myelodysplastic Syndromes
1
Metastasis From Malignant Tumor of Kidney (Disorder)
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Imatinib Mesylate
86
nilotinib
59
fludarabine phosphate
46
Cyclophosphamide
45
Mycophenolic Acid
37
Whole-Body Irradiation
35
Dasatinib
32
fludarabine
31
Tacrolimus
29
Cyclosporine
24
Busulfan
23
Peripheral Blood Stem Cell Transplantation
22
Methotrexate
20
bosutinib
18
Cytarabine
18
Granulocyte Colony-Stimulating Factor
16
Filgrastim
16
Melphalan
14
thymoglobulin
13
Antilymphocyte Serum
13
Stem Cell Transplantation
12
sargramostim
11
Thiotepa
11
Interferon-alpha
10
Cord Blood Stem Cell Transplantation
9
ponatinib
8
asciminib
8
Cyclosporins
8
Sirolimus
7
Radiotherapy
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Immunotherapy, Active
×
Clear all
NCT01819558
2015-03-20
ALLO-WT1
Institut Paoli-Calmettes
Phase 1/2
Completed
2 enrolled